Table 2 Inhibition of cellular viability
From: Oral proteasome inhibitor with strong preclinical efficacy in myeloma models
Cell line | Tumor type | IC50 (nM) |
|---|---|---|
RPMI8226 | Multiple myeloma | 6 ~ 12 |
MM.1S | Multiple myeloma | 3 ~ 6 |
U2932 | Activated B-cell like diffuse large B-cell lymphoma | 6 ~ 9 |
SU-DHL-8 | Diffuse large B-cell lymphoma | 11 ~ 18 |
HCT116 | Colorectal carcinoma | 13 ~ 14 |
HT-29 | Colorectal adenocarcinoma | 11 ~ 16 |
H1650 | Lung carcinoma | 7 ~ 22 |
NCI-H1975 | Lung carcinoma | 2 ~ 14 |
MDA-MB-231 | Breast adenocarcinoma | 8 ~ 14 |
MCF-7 | Breast adenocarcinoma | 14 ~ 25 |